Half Year 2021 Synairgen PLC Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the virtual briefing of Synairgen's unaudited half-year financial results for the six months ending June 30, 2021. As a reminder, participants watching the webcast can submit questions at any time during the presentation using the ask a question button. Please note that these questions will be answered after the event.
I will now hand over to Richard Marsden, Chief Executive Officer of Synairgen, to begin the presentation. Please go ahead.
Hello. My name is Richard Marsden; I am CEO of Synairgen. And I'm going to give you a full update today on the progress we've made developing SNG001 as a broad-spectrum antiviral directed at COVID-19 patients who are in hospital.
SNG001 is an inhaled formulation delivered by a specific nebulizer. And the formulation contains a protein called interferon beta, which is a key cytokine that has been likened to the conductor of an orchestrator.
It drives many antiviral pathways in cells. And the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
